In this article, we will list the 5 Stocks That Have the Potential to Rise 1000%. Please visit 10 Stocks That Have the Potential to Rise 1000% if you would like to see the extended list and the methodology behind it.
5. Zai Lab Limited (NASDAQ:ZLAB)
On May 21, 2026, Zai Lab Limited (NASDAQ:ZLAB) announced senior leadership changes aimed at improving operational performance and efficiency. As part of the changes, the Board decided that Josh Smiley, President and COO, will no longer be with the company, effective May 22. Zai Lab also said it expects multiple clinical data readouts in 2026 for its lead global investigational therapies, including zoci in first-line ES-SCLC and extrapulmonary NECs, and ZL-1503, while preparing for the launch of COBENFY in China and other regional regulatory approvals and data readouts.
On May 11, 2026, Zai Lab Limited (NASDAQ:ZLAB) announced that the U.S. Food and Drug Administration granted Fast Track Designation to zocilurtatug pelitecan, its potential first-in-class DLL3-targeting antibody-drug conjugate, for extrapulmonary neuroendocrine carcinomas after progression following standard first-line therapy. Zai Lab said preliminary data from an ongoing Phase 1b/2 trial showed an objective response rate of 38.2% in heavily pretreated patients.
On May 8, Citi lowered the firm’s price target on Zai Lab to $44 from $47 and maintained a Buy rating on the shares after updating its model following the Q1 report.
A day earlier, Zai Lab Limited (NASDAQ:ZLAB) reported Q1 EPS of (4c), compared to the consensus estimate of (53c). Revenue totaled $99.6M, versus the consensus estimate of $108.43M. CEO Samantha Du said the company continues to accelerate its global pipeline, citing progress in zoci, collaborations with Amgen and Boehringer Ingelheim, and advancement of ZL-1503 for atopic dermatitis. COO Josh Smiley said Zai Lab is deepening its presence in key markets to support VYVGART demand and preparing for the China launch of KarXT in Q2.
Zai Lab Limited (NASDAQ:ZLAB) discovers, develops, and commercializes products for oncology, immunology, neuroscience, and infectious diseases.
4. Rapport Therapeutics, Inc. (NASDAQ:RAPP)
On May 21, 2026, BTIG raised the firm’s price target on Rapport Therapeutics, Inc. (NASDAQ:RAPP) to $65 from $53 and maintained a Buy rating on the shares. BTIG cited clinical execution behind its more constructive stance on RAP-219 in bipolar mania, with Phase 2 topline results pulled forward to Q4 from the first half of FY27 due to steady, uniform enrollment.
On May 18, 2026, Truist assumed coverage of Rapport Therapeutics, Inc. (NASDAQ:RAPP) with a Buy rating and a price target of $56, up from $44. Truist said its thesis remains largely consistent with its prior view, seeing RAP-219 as an attractive, differentiated epilepsy asset. The firm cited early efficacy data suggesting best-in-category potential in focal onset seizures, along with upside optionality in bipolar mania that is not reflected in current projections.
Earlier in May, Rapport Therapeutics, Inc. (NASDAQ:RAPP) reported Q1 EPS of (42c), compared to the consensus estimate of (71c). Revenue totaled $20,000, below the consensus estimate of $6M. CEO Abraham N. Ceesay said Rapport entered 2026 with “strong momentum” across the RAP-219 development program, supported by Phase 2a follow-up data in focal onset seizures and progress toward Phase 3 trials. Ceesay also cited upcoming milestones in epilepsy, bipolar mania, and the company’s long-acting injectable formulation.
Rapport Therapeutics, Inc. (NASDAQ:RAPP) is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for central nervous system disorders.
3. Ascentage Pharma Group International (NASDAQ:AAPG)
On May 31, 2026, Ascentage Pharma Group International (NASDAQ:AAPG) announced Phase Ib results evaluating olverembatinib in combination with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. The data were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology Annual Meeting. Ascentage Pharma said 91% of patients achieved complete response or complete response with incomplete hematologic recovery, while 67% achieved BCR::ABL1 negativity by PCR and 80% achieved MRD negativity by flow cytometry.
Also on May 31, Ascentage Pharma Group International (NASDAQ:AAPG) presented its first dataset for alrizomadlin, an MDM2-p53 inhibitor, as monotherapy or in combination with lisaftoclax in pediatric patients with relapsed/metastatic rhabdomyosarcoma or other soft-tissue sarcomas. In the monotherapy arm, one patient with refractory RMS achieved a complete response. In the combination arm, the ORR was 23.5% among 17 response-evaluable pediatric patients with relapsed/refractory solid tumors, while the disease control rate was 70.6%.
In April, Deutsche Bank initiated coverage of Ascentage Pharma Group International (NASDAQ:AAPG) with a Buy rating and a $40 price target. Deutsche Bank cited two “de-risked, commercially validated” mechanisms in olverembatinib and lisaftoclax, and said lisaftoclax is positioned for continued commercial traction in China.
Ascentage Pharma Group International (NASDAQ:AAPG) develops therapies for cancers, chronic hepatitis B virus, and age-related diseases in Mainland China.
2. GH Research PLC (NASDAQ:GHRS)
On May 19, 2026, H.C. Wainwright lowered the firm’s price target on GH Research PLC (NASDAQ:GHRS) to $65 from $70 and maintained a Buy rating on the shares. H.C. Wainwright cited share count dilution from the company’s April offering for the target cut.
On May 15, 2026, Cantor Fitzgerald raised the firm’s price target on GH Research PLC (NASDAQ:GHRS) to $35 from $25 and maintained an Overweight rating on the shares. Cantor Fitzgerald said GH Research operates in a large and expanding psychedelic therapy market with significant unmet mental health needs. The firm said long-term peak sales across related treatments could reach roughly $50B, supporting a constructive demand backdrop despite uncertainty around competitive dynamics.
A day earlier, GH Research PLC (NASDAQ:GHRS) reported Q1 EPS of (31c), compared to the consensus estimate of (26c). CEO Velichka Valcheva said the quarter marked progress toward the company’s global GH001 Phase 3 pivotal program.
GH Research PLC (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company developing treatments for depression in the United States.
1. Biohaven Ltd. (NYSE:BHVN)
On June 1, 2026, Biohaven Ltd. (NYSE:BHVN) announced the initiation of first-in-human dosing for BHV-8100, its oral, brain-penetrant pyruvate kinase M2 isoform modulator. Chief Scientific Officer Bruce Car said BHV-8100 represents a potential “fundamental breakthrough” in a new class of medicines for systemic and brain disorders involving metabolic and immune dysfunction. Car said Biohaven is seeking to correct the core energy deficit linked to inflammatory and neurological disorders, including atopic dermatitis, Alzheimer’s disease, and retinitis pigmentosa.
On May 27, 2026, Biohaven Ltd. (NYSE:BHVN) reported “compelling” results from its extracellular MoDE and TRAP degrader platform, including BHV-1300 and BHV-1400. In Graves’ Disease, weekly BHV-1300 1000 mg achieved mean reductions of pathogenic TSHR-IgG1 of greater than 80% by week 12, while patients with elevated thyroid hormones saw free T4 normalize at a median of 3 weeks and free T3 within a median of 5 weeks. Biohaven said BHV-1300 has been safe and well-tolerated through 12 weeks of dosing and is being advanced to a pivotal trial in Graves’ disease in the coming weeks. For BHV-1400 in IgA nephropathy, the company said treatment achieved mean reductions of pathogenic Gd-IgA1 of greater than 60% within 48 hours and 70% within one month of dosing.
Earlier in May, RBC Capital lowered the firm’s price target on Biohaven Ltd. (NYSE:BHVN) to $22 from $23 and maintained an Outperform rating on the shares. RBC said the company’s Q1 results showed programs progressing as expected ahead of its R&D Day, while noting that pivotal initiations for BHV-1400 are taking slightly longer into mid-2026.
Biohaven Ltd. (NYSE:BHVN) focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.
While we acknowledge the potential of BHVN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BHVN and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 High Growth Stocks to Buy and Hold for the Next Decade and 12 Strong Buy Stocks to Buy and Hold for the Next 5 Years
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
